title: Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review.
abstract: OBJECTIVE
  It is controversial whether patients with non-ulcer dyspepsia (NUD) respond differently to Helicobacter pylori (H pylori) eradication treatment than those with peptic ulcer disease (PUD). To review the evidence for any difference in H pylori eradication rates between PUD and NUD patients.
  
  
  METHODS
  A literature search for full articles and meeting abstracts to July 2004 was conducted. We included studies evaluating the efficacy of a proton pump inhibitor (P) or ranitidine bismuth citrate (RBC) plus two antibiotics of clarithromycin (C), amoxicillin (A), metronidazole (M), or P-based quadruple therapies for eradicating the infection.
  
  
  RESULTS
  Twenty-two studies met the criteria. No significant difference in eradication rates was found between PUD and NUD patients when treated with 7-d RBCCA, 10-d PCA or P-based quadruple therapies. When the 7-d PCA was used, the pooled H pylori eradication rate was 82.1% (431/525) and 72.6% (448/617) for PUD and NUD patients, respectively, yielding a RR of 1.15 (95%CI 1.01-1.29). However, the statistically significant difference was seen only in meeting abstracts, but not in full publications.
  
  
  CONCLUSIONS
  There is no convincing evidence to suggest that NUD patients respond to H pylori eradication treatments differently from those with PUD, although a trend exists with the 7-d PCA therapy.
authors.affiliation: Department of Medicine, Faculty of Medicine, University of Hong Kong, Hong Kong, China.
authors.forename: Jia-Qing
authors.initials: JQ
authors.lastname: Huang
authors.forename: Ge-Fan
authors.initials: GF
authors.lastname: Zheng
authors.forename: Richard H
authors.initials: RH
authors.lastname: Hunt
authors.forename: Wai-Man
authors.initials: WM
authors.lastname: Wong
authors.forename: Shiu-Kum
authors.initials: SK
authors.lastname: Lam
authors.forename: Johan
authors.initials: J
authors.lastname: Karlberg
authors.forename: Benjamin Chun-Yu
authors.initials: BC
authors.lastname: Wong
mesh_terms: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004415:Dyspepsia / Q000382:microbiology*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D010437:Peptic Ulcer / Q000382:microbiology*; D054328:Proton Pump Inhibitors; D011899:Ranitidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; C073340:ranitidine bismuth citrate; D011899:Ranitidine; D001729:Bismuth